气候变化领域集成服务门户(CCPortal): Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody

CCPortal

DOI	10.1073/pnas.2023332118
	Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody
	Zeitlin L.; Cross R.W.; Geisbert J.B.; Borisevich V.; Agans K.N.; Prasad A.N.; Enterlein S.; Aman M.J.; Bornholdt Z.A.; Brennan M.B.; Campbell L.; Kim D.; Mlakar N.; Moyer C.L.; Pauly M.H.; Shestowsky W.; Whaley K.J.; Fenton K.A.; Geisbert T.W.
发表日期	2021
ISSN	00278424
卷号	118 期号:11
英文摘要	The COVID-19 pandemic has reemphasized the need to identify safe and scalable therapeutics to slow or reverse symptoms of disease caused by newly emerging and reemerging viral pathogens. Recent clinical successes of monoclonal antibodies (mAbs) in therapy for viral infections demonstrate that mAbs offer a solution for these emerging biothreats. We have explored this with respect to Junin virus (JUNV), an arenavirus classified as a category A high-priority agent and the causative agent of Argentine hemorrhagic fever (AHF). There are currently no Food and Drug Administration-approved drugs available for preventing or treating AHF, although immune plasma from convalescent patients is used routinely to treat active infections. However, immune plasma is severely limited in quantity, highly variable in quality, and poses significant safety risks including the transmission of transfusionborne diseases. mAbs offer a highly specific and consistently potent alternative to immune plasma that can be manufactured at large scale. We previously described a chimeric mAb, cJ199, that provided protection in a guinea pig model of AHF. To adapt this mAb to a format more suitable for clinical use, we humanized the mAb (hu199) and evaluated it in a cynomolgus monkey model of AHF with two JUNV isolates, Romero and Espindola. While untreated control animals experienced 100% lethality, all animals treated with hu199 at 6 d postinoculation (dpi) survived, and 50% of animals treated at 8 dpi survived. mAbs like hu199 may offer a safer, scalable, and more reproducible alternative to immune plasma for rare viral diseases that have epidemic potential. © 2021 National Academy of Sciences. All rights reserved.
英文关键词	Hemorrhagic fever; Junin; Monoclonal; Therapy
语种	英语
scopus关键词	monoclonal antibody; virus antibody; American hemorrhagic fever; animal; blood; disease model; female; guinea pig; human; Junin virus; Macaca fascicularis; metabolism; Animals; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Disease Models, Animal; Female; Guinea Pigs; Hemorrhagic Fever, American; Humans; Junin virus; Macaca fascicularis
来源期刊	Proceedings of the National Academy of Sciences of the United States of America
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/180231
作者单位	Mapp Biopharmaceutical, Inc., San Diego, CA 92121, United States; Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX 77555, United States; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, United States; Integrated BioTherapeutics, Inc., Gaithersburg, MD 20878, United States
推荐引用方式 GB/T 7714	Zeitlin L.,Cross R.W.,Geisbert J.B.,et al. Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody[J],2021,118(11).
APA	Zeitlin L..,Cross R.W..,Geisbert J.B..,Borisevich V..,Agans K.N..,...&Geisbert T.W..(2021).Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody.Proceedings of the National Academy of Sciences of the United States of America,118(11).
MLA	Zeitlin L.,et al."Therapy for Argentine hemorrhagic fever in nonhuman primates with a humanized monoclonal antibody".Proceedings of the National Academy of Sciences of the United States of America 118.11(2021).